Virios Logo Blue.jpg
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
18 sept. 2023 07h05 HE | Virios Therapeutics
ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Virios Logo Blue.jpg
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
12 sept. 2023 07h05 HE | Virios Therapeutics
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Virios Logo Blue.jpg
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
14 août 2023 07h05 HE | Virios Therapeutics
ATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Logo Blue.jpg
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 août 2023 07h05 HE | Virios Therapeutics
- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the...
Virios Logo Blue.jpg
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
09 août 2023 07h05 HE | Virios Therapeutics
ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Logo Blue.jpg
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
03 août 2023 16h05 HE | Virios Therapeutics
ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral...
Virios Logo Blue.jpg
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
17 juil. 2023 07h05 HE | Virios Therapeutics
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Logo Blue.jpg
Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
25 mai 2023 16h05 HE | Virios Therapeutics
ATLANTA, May 25, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with...
Virios Logo Blue.jpg
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
15 mai 2023 07h05 HE | Virios Therapeutics
ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Logo Blue.jpg
Virios Therapeutics Announces First Quarter 2023 Financial Results
11 mai 2023 07h05 HE | Virios Therapeutics
ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...